Welcome to our dedicated page for Owlet SEC filings (Ticker: OWLTW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Owlet's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Owlet's regulatory disclosures and financial reporting.
Owlet, Inc. (OWLT): Director Form 4 filing — On 10/10/2025, a director acquired 107,626 shares of Class A common stock. Following the transaction, the director beneficially owns 233,030 shares, held directly.
The shares were issued in exchange for previously held warrants tied to the company’s Series A (February 2023) and Series B (February 2024) preferred financings, at approximate exchange ratios of 0.61 and 0.56 shares per warrant. Two warrant positions for 131,195 and 48,621 underlying shares were disposed, leaving zero derivative securities.
Owlet, Inc. (OWLT): A reporting person acquired 686,469 shares of common stock on October 10, 2025 via an exchange of previously issued warrants and now directly owns 1,567,468 shares.
The transaction exchanged warrants issued in connection with the company’s Series A and Series B financings for common shares at approximate ratios of 0.61 and 0.56 shares per warrant, respectively. Specifically, 712,915 warrants initially issued on 02/17/2023 (expiring 02/17/2028) and 444,601 warrants initially issued on 02/29/2024 (expiring 03/01/2029) were converted (Transaction Code C). Following the exchange, the reported balance of these derivative securities is 0.
Trilogy Equity Partners filed Amendment No. 4 to its Schedule 13D on Owlet, Inc. (Class A Common Stock), reporting beneficial ownership of 2,022,178 shares, or approximately 8.7% of the class.
The reported stake consists of 1,567,468 common shares, plus 158,309 shares issuable upon conversion of Series A Convertible Preferred and 296,401 shares issuable upon conversion of Series B Convertible Preferred, as disclosed. Owlet had 22,788,420 shares outstanding as of October 10, 2025.
Trilogy has sole voting and dispositive power over the reported shares. On October 10, 2025, Trilogy exchanged 712,915 Series A-related warrants and 444,601 Series B-related warrants for common shares at exchange ratios of 0.61 and 0.56 shares per warrant, respectively.
Owlet, Inc. (OWLT) received an amended Schedule 13D (Amendment No. 5) from Eclipse-affiliated funds and Lior Susan, updating beneficial ownership and disclosing a completed warrant-for-share exchange. On October 10, 2025, Eclipse Early Growth Fund I exchanged 5,300,921 Series A Warrants and 1,166,935 Series B Warrants for 3,898,906 Class A shares for no additional consideration.
Reported beneficial holdings include: Eclipse Continuity Fund I at 1,066,472 shares (4.7%), Eclipse Ventures Fund I at 968,694 shares (4.3%), and Eclipse Early Growth Fund I at 7,621,469 shares (30.8%), which includes 1,955,800 shares issuable upon preferred stock conversion. Lior Susan is reported at 9,656,635 shares (40.5%). Percentages reference 22,788,420 Class A shares outstanding as of October 14, 2025.
Owlet, Inc. (OWLT): Eclipse-affiliated holders reported an exchange of previously issued warrants for common stock on October 10, 2025. Eclipse Early Growth Fund I, L.P. acquired 3,898,906 shares of common stock in the exchange, and the related Series A and Series B warrants were disposed.
Following the transactions, 5,665,669 shares were beneficially owned indirectly (per footnote (2)). Other Eclipse-managed funds reported indirect holdings of 968,694 shares (per footnote (3)) and 1,066,472 shares (per footnote (4)). The filing identifies the reporting persons as Director, 10% Owner, and “Director by Deputization.”
The exchange covered warrants originally issued in February 2023 (Series A) and February 2024 (Series B) at approximate exchange ratios of 0.61 and 0.56 shares per warrant, respectively, and is noted as exempt under Rule 16b-3.